Investigational Drug Details
| Drug ID: | D356 |
| Drug Name: | Ceftriaxone |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB01212 |
| DrugBank Description: | A broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. |
| PubChem ID: | 5479530 |
| CasNo: | 73384-59-5 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O |
| Structure: |
|
| InChiKey: | VAAUVRVFOQPIGI-SPQHTLEESA-N |
| Molecular Weight: | 554.58 |
| DrugBank Targets: | Penicillin-binding protein 2B; Solute carrier family 22 member 11; Solute carrier family 22 member 6; Solute carrier family 22 member 8; Solute carrier family 15 member 1 |
| DrugBank MoA: | Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death. |
| DrugBank Pharmacology: | Ceftriaxone is a cephalosporin/cephamycin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. Ceftriaxone has <i>in vitro</i> activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Ceftriaxone results from the inhibition of cell wall synthesis and is mediated through Ceftriaxone binding to penicillin binding proteins (PBPs). Ceftriaxone is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. |
| DrugBank Indication: | For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L4260 | NCT00653341 | PHASE3 | COMPLETED | NO | 2000-01 | 2009-04-20 | Details |
| L4264 | NCT01526941 | PHASE1 | COMPLETED | NO | 2001-05 | 2017-01-05 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|